AI
Wednesday, April 18, 2018 8:10:48 AM
CYTR - 1.92 Pre-market now at 2.07/2.10
CytRx Says LADR-7, LADR-8, LADR-9 and LADR-10 Demonstrate Robust Complete and Partial Responses and Long-Term Antitumor Activity in Melanoma, Lung, Breast, Ovarian, Head and Neck and Renal Cell Cancers; Conf. Call Today At 11 a.m.
CytRx Says LADR-7, LADR-8, LADR-9 and LADR-10 Demonstrate Robust Complete and Partial Responses and Long-Term Antitumor Activity in Melanoma, Lung, Breast, Ovarian, Head and Neck and Renal Cell Cancers; Conf. Call Today At 11 a.m.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
